Clinical Trials · NCT04563936
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Luye Pharma Group Ltd.
- Enrollment
- 290
- Start date
- Jan 2020
- Locations
- 1 site, China
- Primary endpoint
- The percentage of subjects with serum testosterone ≤50 ng/dL (1.735 nmol/L) on Day 29 after the first dose.